Compare Regeneron Pharmaceuticals Inc (REGN) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Star Bulk Carriers Corp — how do they compare? Regeneron Pharmaceuticals Inc trades at $746.54 (market cap $76.14B), while Star Bulk Carriers Corp trades at $29.7 (market cap $3.54B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 21.5× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays the higher dividend (6.17%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Star Bulk Carriers Corp for 24 Days on average.
| REGN | SBLK | |
|---|---|---|
Market Cap | $76.14B | $3.54B |
Volume | 500,239 | 1,437,622 |
Sector | Health | Industrials |
52-Week High | $852.03 | $32.49 |
52-Week Low | $557.73 | $16.79 |
Typical Hold Time | 107 Days | 24 Days |
Enterprise Value | $70.85B | $4.22B |
Dividend Yield | 0.51% | 6.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, down 0.34% with a bearish technical signal. The company maintains strong fundamentals with a 27.86% net income margin and consistent earnings beats. Recent news highlights a significant $8 billion immunology alliance expansion with Sanofi, providing substantial upfront payments and milestone potential. Cash flow improved significantly in 2025 with $635 million net cash flow versus negative flows in prior years.
The stock presents a compelling investment case with strong profitability, positive analyst sentiment (69% buy ratings), and a $849.84 consensus price target offering 15% upside. Key risks include competitive pressures in ophthalmology drugs and reliance on key partnerships. The expanded Sanofi collaboration and promising clinical pipeline provide catalysts for growth.
Star Bulk Carriers (SBLK) trades at $30.47, up 2.63% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. The company reported strong Q2 2026 EPS of $1.21, exceeding expectations, and maintains a 100% free cash flow distribution policy, highlighted by a $0.90 dividend for H2 2026. Valuation metrics show a P/E of 11.95 and EV/EBITDA of 8.34, indicating reasonable pricing relative to earnings.
The outlook remains positive due to robust earnings growth, shareholder returns, and insider buying, but risks include shipping market volatility and reliance on global trade cycles. Analyst consensus is bullish with 14 buy ratings, supporting potential upside if operational momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
